Petosemtamab
Sponsors
Genmab A/S, Merus B.V., Genmab
Conditions
Colorectal CancerHead and Neck Squamous Cell CarcinomaLeft-sided Colorectal Cancer
Phase 3
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Active, not recruitingNCT06496178
Start: 2024-06-25End: 2029-03-01Updated: 2026-10-19
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Active, not recruitingNCT06525220
Start: 2024-09-25End: 2030-07-01Updated: 2026-09-25
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
RecruitingNCT07702032
Start: 2026-08-11End: 2031-09-01Target: 960Updated: 2026-10-06
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
RecruitingNCT07775287
Start: 2026-10-07End: 2030-01-31Target: 600Updated: 2026-10-09
A Randomized, Open-label, Phase 3 Trial of Petosemtamab in Combination With mFOLFOX6 or FOLFIRI Versus Cetuximab in Combination With mFOLFOX6 or FOLFIRI as First-line Treatment for Participants With RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
Not yet recruitingCTIS2026-525883-17-00
Target: 159Updated: 2026-10-20